The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis.
acute myocardial infarction
angiotensin receptor‐neprylisin Inihibitors
heart failure
medical therapy
sacubitril
valsartan
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
revised:
26
08
2024
received:
11
06
2024
accepted:
04
09
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
There is a need to address the evidence gap regarding the in-hospital administration of sacubitril/valsartan in acute myocardial infarction patients. After searching MEDLINE, Google Scholars and Scopus, a random-effects meta-analysis of randomized controlled trials comparing the in-hospital administration of the angiotensin receptor-neprilysin inhibitors (ARNis) versus the standard therapy in patients with reduced heart failure due to myocardial infarction was performed. The primary outcome was major adverse cardiovascular events. All-cause mortality, cardiac death, rehospitalization for heart failure, non-fatal myocardial infarction (MI), changes in left ventricular ejection fraction, left ventricular volumes, N terminal pro brain natriuretic peptide and adverse events were the secondary endpoints. Nine studies (eight randomized controlled trials and one echo-substudy) with a total 6597 individuals (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker: 3300 patients vs. ARNis: 3297 patients) were included for quantitative analysis. Median follow-up was 6 months. Patients receiving an in-hospital coadministration of ARNi had a lower risk of major cardiovascular event [odds ratio (OR) 0.45, 95% confidence interval (CI) 0.32-0.63, P < 0.0001] and lower rate of repeat rehospitalization for heart failure (OR 0.40, 95% CI 0.26-0.62, P < 0.0001), compared with a standard regimen. Additionally, left ventricle volumes were significantly lower in the ARNi group [left ventricular end-diastolic volume, mean difference (MD) 11.48 mL, 95% CI 6.10-16.85, P < 0.0001; left ventricular end-systolic volume, MD 7.09 mL, 95% CI 2.89-11.29, P = 0.0009] with a significant change in left ventricular ejection fraction (MD 3.07, 95% CI 1.61-4.53, P < 0.0001), compared with standard therapy. No significant differences were observed in terms of cardiac death, all cause of mortality, non-fatal myocardial infarction and N terminal pro brain natriuretic peptide. Higher rates of iatrogenic hypotensive events were observed in the ARNi group compared with the standard therapy (OR 1.42, 95% CI 1.26-1.60, P value < 0.00001). In patients with acute myocardial infarction related heart failure, the in-hospital administration of ARNis was associated with a reduced risk of major cardiovascular events and re-hospitalization for heart failure, as well as cardiac remodelling, but higher rates of hypotensive events compared with standard therapy.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post‐myocardial infarction patients: nationwide real world data demonstrate the importance of a long‐term perspective. Eur Heart J 2015;36:1163‐1170. doi:10.1093/eurheartj/ehu505
Tobbia P, Brodie BR, Witzenbichler B, Metzger C, Guagliumi G, Yu J, et al. Adverse event rates following primary PCI for STEMI at US and non‐US hospitals: three‐year analysis from the HORIZONS‐AMI trial. EuroIntervention 2013;8:1134‐1142. doi:10.4244/EIJV8I10A176
De Filippo O, D'Ascenzo F, Wańha W, et al. IncidenCe and predictOrs of heaRt fAiLure after acute coronarY syndrome: the CORALYS registry. Int J Cardiol 2023 Jan;1:35‐42.
Bruno F, Marengo G, De Filippo O, et al. Impact of complete revascularization on development of heart failure in patients with acute coronary syndrome and multivessel disease: a subanalysis of the CORALYS registry. J Am Heart Assoc 2023 Aug;12:e028475. doi:10.1161/JAHA.122.028475
Sulo G, Igland J, Vollset SE, Nygård O, Ebbing M, Sulo E, et al. Burden and timing of occurrence: a nation‐wide analysis including 86 771 patients from the cardiovascular disease in Norway (CVDNOR) project. J Am Heart Assoc 2016;5:e002667. doi:10.1161/JAHA.115.002667
Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no‐reflow in humans. J Am Coll Cardiol 2009;54:281‐292.
Severino P, D'Amato A, Prosperi S, et al. Myocardial infarction with non‐obstructive coronary arteries (MINOCA): focus on coronary microvascular dysfunction and genetic susceptibility. J Clin Med 2023;12:3586. doi:10.3390/jcm12103586
Gatto L. Does sacubitril/valsartan work in acute myocardial infarction? The PARADISE‐AMI study. Eur Heart J Suppl 2021;23:E87‐E90. doi:10.1093/eurheartj/suab098
Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992;327:669‐677. doi:10.1056/NEJM199209033271001
The acute infarction ramipril efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821‐828.
Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752‐760. doi:10.1016/S0140‐6736(02)09895‐1
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893‐1906. doi:10.1056/NEJMoa032292
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 2024;13:55‐161.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599‐3726. doi:10.1093/eurheartj/ehab368
Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond) 1996;91:283‐291. doi:10.1042/cs0910283
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993‐1004. doi:10.1056/NEJMoa1409077
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin‐neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539‐548. doi:10.1056/NEJMoa1812851
Maggioni AP. PARADISE‐MI: another example why the results of a trial should not be considered as those of a soccer game. G Ital Cardiol (Rome) 2022;23:157‐159. Italian. doi:10.1714/3751.37331
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;29:n71.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin receptor‐Neprilysin inhibition in acute myocardial infarction. N Engl J Med 2021;385:1845‐1855. doi:10.1056/NEJMoa2104508
Rezq A, Saad M, El Nozahi M. Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST‐segment elevation myocardial infarction. Am J Cardiol 2021;15:7‐13.
Yang P, Li X, Wang L, Wu X, Wang C, Li T, et al. Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction. Front Cardiovasc Med 2023;13:1059420.
Dong Y, Xu Y, Ding C, Yu Z, Yu Z, Xia X, et al. Comparing the efficacy of angiotensin receptor‐neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial. Cardiovasc Diagn Ther 2022;12:42‐54. doi:10.21037/cdt‐21‐386
Fan H, Wang Y, Wang X, Dong X, Shao X, Yang F. Effect of emergency percutaneous coronary intervention combined with sacubitril and valsartan on the cardiac prognosis in patients with acute myocardial infarction. Int J Gen Med 2023;7:499‐505.
Abdelnabi M, Saleh Y, Benjanuwattra J, Badran H, Almaghraby A. The role of sacubitril/valsartan in post‐acute myocardial infarction (RSVP‐AMI trial). J Am Coll Cardiol 2023;81:1331.
Zhang Y, Wu Y, Zhang K, Ke Z, Hu P, Jin D. Benefits of early administration of sacubitril/valsartan in patients with ST‐elevation myocardial infarction after primary percutaneous coronary intervention. Coron Artery Dis 2021;32:427‐431. doi:10.1097/MCA.0000000000000955
Wang H, Fu X. Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coron Artery Dis 2021;32:418‐426. doi:10.1097/MCA.0000000000000932
Shah AM, Claggett B, Prasad N, Li G, Volquez M, Jering K, et al. Impact of sacubitril/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: the PARADISE‐MI echocardiographic substudy. Circulation 2022;146:1067‐1081. doi:10.1161/CIRCULATIONAHA.122.059210
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. doi:10.1136/bmj.l4898
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ 2016 Oct;12:i4919.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383‐394. doi:10.1016/j.jclinepi.2010.04.026
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627‐3639. doi:10.1093/eurheartj/ehad195
Gu J, Wang Y, Wang CQ, Zhang JF. The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Eur J Intern Med 2023;112:62‐69. doi:10.1016/j.ejim.2023.03.019
She J, Lou B, Liu H, Zhou B, Jiang GT, Luo Y, et al. ARNI versus ACEI/ARB in reducing cardiovascular outcomes after myocardial infarction. ESC Hear Fail 2021;8:4607‐4616. doi:10.1002/ehf2.13644
Xiong B, Nie D, Qian J, Yao Y, Yang G, Rong S, et al. The benefits of sacubitril‐valsartan in patients with acute myocardial infarction: a systematic review and meta‐analysis. ESC Hear Fail 2021;8:4852‐4862. doi:10.1002/ehf2.13677
Yang P, Han Y, Lian C, Wu X. Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: a meta‐analysis. Front Cardiovasc Med. 2022;9:988117. doi:10.3389/fcvm.2022.1120085
Moon MG, Hwang IC, Choi W, Cho GY, Yoon YE, Park JB, et al. Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction. ESC Hear Fail 2021;8:2058‐2069. doi:10.1002/ehf2.13285
Leancă SA, Crișu D, Petriș AO, Afrăsânie I, Genes A, Costache AD, et al. Left ventricular remodeling after myocardial infarction: from physiopathology to treatment. Life (Basel, Switzerland) 2022;12:1111. doi:10.3390/life12081111
Frantz S, Hundertmark MJ, Schulz‐Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post‐myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J 2022;43:2549‐2561. doi:10.1093/eurheartj/ehac223
Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008;29:1485‐1494. doi:10.1093/eurheartj/ehn206
Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, et al. C‐type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 2005;45:608‐616.
Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post‐infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 2011;16:13‐21. doi:10.1007/s10741‐010‐9181‐7
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2024;349:1893‐1906.
Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Køber L, et al. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. Eur Heart J 2009;30:56‐65. doi:10.1093/eurheartj/ehn499
Naruko T, Ueda M, van der Wal AC, van der Loos CM, Itoh H, Nakao K, et al. C‐type natriuretic peptide in human coronary atherosclerotic lesions. Circulation 1996;94:3103‐3108. doi:10.1161/01.CIR.94.12.3103
Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor‐C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium‐derived C‐type natriuretic peptide. Circulation 2004;110:1231‐1235. doi:10.1161/01.CIR.0000141802.29945.34
Kohno M, Yokokawa K, Yasunari K, Kano H, Minami M, Ueda M, et al. Effect of natriuretic peptide family on the oxidized LDL‐induced migration of human coronary artery smooth muscle cells. Circ Res 1997;81:585‐590. doi:10.1161/01.RES.81.4.585
Mogensen UM, Køber L, Kristensen SL, Jhund PS, Gong J, Lefkowitz MP, et al. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM‐HF. Am Heart J 2017;188:35‐41. doi:10.1016/j.ahj.2017.02.034
Mehran R, Steg PG, Pfeffer MA, Jering K, Claggett B, Lewis EF, et al. The effects of angiotensin receptor‐Neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE‐MI trial. Circulation 2022;146:1749‐1757. doi:10.1161/CIRCULATIONAHA.122.060841